The phase III IMbrave-150 study of atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF) therapy was the first to demonstrate a survival benefit over sorafenib in the first-line setting and has become the standard of care in advanced HCC.4 This evidence concerns the gene CD274 and hepatocellular carcinoma.